Toll-like receptors in Alzheimer's disease.

Alzheimer disease Amyloid-beta Inflammation Microglia Single nucleotide polymorphisms Toll-like receptor

Journal

Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498

Informations de publication

Date de publication:
15 11 2020
Historique:
received: 30 06 2020
revised: 04 08 2020
accepted: 15 08 2020
pubmed: 29 8 2020
medline: 15 12 2020
entrez: 29 8 2020
Statut: ppublish

Résumé

Neuroinflammation and microglial dysfunction are key contributors to the development of Alzheimer's disease (AD). Toll-like receptors (TLRs) are transmembrane proteins primarily involved in immune responses and expressed by several immune and non-immune cells within the central nervous system. Signaling of TLRs affects the core of AD changes, including synaptic plasticity, microglial activity, tau phosphorylation, and inflammatory responses. We reviewed the activity, expression, potential applications, and genetic polymorphisms of TLRs in AD. Activation of TLRs has shown both destructive and protective effects. Several genetic polymorphisms of TLRs have been also recognized as protective or risk factors for AD. We concluded that TLRs are one of the major components of AD pathogenesis, particularly in the early stages of the disease, which can provide novel therapeutic options.

Identifiants

pubmed: 32858428
pii: S0165-5728(20)30432-X
doi: 10.1016/j.jneuroim.2020.577362
pii:
doi:

Substances chimiques

Toll-Like Receptors 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

577362

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no competing interests.

Auteurs

Sara Momtazmanesh (S)

School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Neuroimmunology Research Association (NIRA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.

George Perry (G)

Department of Biology and Neurosciences Institute, University of Texas at San Antonio (UTSA), San Antonio, TX, USA.

Nima Rezaei (N)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran. Electronic address: rezaei_nima@tums.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH